The National Osteoporosis Foundation (NOF), which recently led a letter to Congress signed by over 300 health advocacy groups opposing harmful government interference in the Medicare Part D program, today issued the following statement in response to S. 1688: āIt is discouraging that, despite direct opposition from over 300 health advocates, members of Congress have… Read more »
BHOF in the News
NOF Response to Newly Released Evidence Report on Cost Effectiveness of Anabolic Therapies for Osteoporosis in Postmenopausal Women from the Institute for Clinical and Economic Review (ICER) »
The Institute for Clinical and Economic Review (ICER) recently issued a Final Evidence Report accessing the comparative clinical effectiveness and value of anabolic agents for the treatment of osteoporosis in postmenopausal women, including teriparatide and abaloparatide.Ā NOF leadership and colleagues representing the National Bone Health Alliance (NBHA) provided input and shared ideas and potential concerns… Read more »
Osteopenia: Causes, treatments, and prevention »
As a person ages, bone density can naturally decrease. Osteopenia is characterized by extremely low bone density, regardless of age. Read the full article about osteopenia vs. osteoporosis here: http://www.medicalnewstoday.com/articles/318321.php.
The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay »
Washington, DC (June 13, 2017) ā The National Osteoporosis Foundation (NOF), today issued the following statement in response to the Senate HELP hearing āThe Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Payā āDuring todayās hearing, several Senators raised the idea of allowing for the government to set prices in the… Read more »
Osteoporosis: ACP update treatment guidelines for preventing bone fractures »
To reduce the risk of hip and vertebral fractures in women with osteoporosis, physicians should treat them with the bisphosphonates risedronate, alendronate, or zoledronic acid, or alternatively with the biologic agent denosumab. This strong recommendation appears in revised guidelines from the American College of Physicians (ACP) for the prevention of fractures in men and women… Read more »
The NOF’s Methods and Processes for Developing Position Statements »
The National Osteoporosis Foundation frequently publishes position statements for the benefit of educating healthcare professionals and the general public on a particular issue and/or concern related to preventing osteoporosis and/or promoting strong bones throughout the lifespan. This manuscript represents the official methods and processes adopted by the NOF Board of Trustees for the purpose developing… Read more »
CMS Proposes New Fee Schedules for 2017 »
On July 14, 2016, the Centers for Medicare and Medicaid Services (CMS) published the proposed rule for the Hospital Outpatient Prospective Payment SystemĀ (HOPPS) for 2017. CMS has proposed to cut the reimbursement rate for Axial DXA, CPT 77080 in the hospital setting from the current national average of $100.69 to $63.33.Ā This reimbursement cut will… Read more »
NOF and ASPC Position Statement on Calcium and Cardiovascular Disease »
The National Osteoporosis Foundation frequently publishes position statements for the benefit of educating healthcare professionals and the general public on a particular issue and/or concern related to preventing osteoporosis and/or promoting strong bones throughout the lifespan. As part of NOFās Methods and Processes for Developing Position Statements, we welcome public input and comments to the… Read more »
Fearing Drugsā Rare Side Effects, Millions Take Their Chances With Osteoporosis »
Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.Ā Last month, the American Society for Bone and Mineral Research, the National Osteoporosis Foundation and the National Bone Health Alliance put out… Read more »
Clinical Trial by Juvent Confirms New Device Improves Bone Density in Cancer Survivors »
One our Corporate Advisory Roundtable members, Juvent, announced very positive results from the St. Jude Childrenās Hospital Clinical Trial. An 11% increase in bone density was seen in childhood cancer survivors through their product,Ā JuventĀ® Dynamic Motion Therapy Platform. The study was published in the Journal of the American Medical Association (JAMA) Oncology. To learn more,… Read more »